Haemonetics completed the acquisition of OpSens for $253m.

Haemonetics, a medical technology company, completed the acquisition of OpSens, a medical device cardiology-focused company, for $253m. "Expanding our Hospital portfolio with OpSens' products creates exciting growth and diversification opportunities, while providing immediately accretive financial benefits. We are pleased to officially welcome OpSens to Haemonetics and look forward to driving greater access to OpSens' essential solutions and benefits for physicians and patients throughout the world," Chris Simon, Haemonetics President and CEO.